Abstract 298P
Background
Abandonment of treatment is a poorly recognized issue, common in the unique group of Teenage and Young Adults (TYAs) (15-29 y) with cancer. Cancer in this age group causes social and psychological turmoil altering their understanding and perception about the management of cancer. This study is the first-of-its kind in TYAs while there are several pediatric reports on the problem.
Methods
A retrospective cross-sectional and analytical study was conducted over a period of 18 months from 01st January 2017 to 30thJune 2018 with a 12-month registration period and 6 months of follow up at four cancer centers in Rajasthan (3) and Madhya Pradesh (1). A total of 1310 TYA cancer patients’ charts were analyzed to study the influence of demographic and disease-related characteristics associated with the abandonment of treatment in TYAs with cancer. Complete data of 807 patients (55.8%) was collected.
Results
Factors leading to abandonment were analyzed, and the salient conclusions are that - Total of 650 patients (80.5%) were from the rural background and most of the patients (88%) were living more than 200 kilometers from oncology centers. A quarter (24.4%) of all TYAs with cancer abandoned their therapy: mostly students, unemployed and unmarried. Those with bone cancer (37%), brain tumor (31.6%) and leukemia (25.1%) had the highest abandonment rate. Reasons for abandonment identified were financial burden of therapy, followed by the refusal of standard therapy and preference for alternative medicine. Mortality rates were Forty six percent in our study group with similar outcome across all age groups. There were significantly more deaths in patients who abandoned treatment. (30.4% vs 18.6%).
Conclusions
Our study has for the first-time quantified abandonment of treatment among TYA cancer patients: a quarter of all cancers. Completing treatment decreases the probability of death from cancer. Conducting a large, community level collaborative study will probably be more informative and could validate these and other characteristics of this unique demographic group of cancer patients, with clues to reduce or prevent abandonment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
153P - Mutational landscape of gastric cancer (GC) in adolescents and young adults (AYA) in Asia from 2015-2019
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
154P - A multicenter, prospective study of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer
Presenter: Yi-Hui Tang
Session: e-Poster Display Session
155P - Surgical outcomes and technical performance of robotic versus laparoscopic total gastrectomy for gastric cancer: A prospective comparative study FUGES-014
Presenter: Hua-Gen Wang
Session: e-Poster Display Session
156P - Safety and feasibility of laparoscopic spleen-preserving splenic hilar lymphadenectomy during total gastrectomy for advanced proximal gastric cancer: A randomized clinical trial
Presenter: Jian-Xian Lin
Session: e-Poster Display Session
157P - Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
Presenter: Amy Prawira
Session: e-Poster Display Session
158P - A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX study): Final report
Presenter: Atsuo Takashima
Session: e-Poster Display Session
159P - Open surgery can improve the 3-year postoperative survival in some patients with advanced gastric cancer compared with laparoscopic surgery: A multicenter, propensity score matching, in-depth analysis
Presenter: Ze-Ning Huang
Session: e-Poster Display Session
160P - Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Ning Li
Session: e-Poster Display Session
161P - Adjuvant tegafur/gimeracil/oteracil (S-1) versus platinum-based chemotherapies for resectable gastric cancer: Real-world experience and a propensity score matching analysis
Presenter: Chih Chieh Yen
Session: e-Poster Display Session
162P - Evaluation of neutrophil/lymphocyte ratio (NLR) in monitoring anastomotic leakage after radical total gastrectomy for gastric cancer
Presenter: Ru-Hong Tu
Session: e-Poster Display Session